Biologics in COPD have so far been eosinophil-directed, which limits them to a minority of patients. Astegolimab, an anti-ST2 monoclonal antibody, targets the alarmin pathway upstream of type 2 inflammation, and the pivotal trials deliberately enrolled without an eosinophil threshold.
This prespecified pooled analysis combines ALIENTO and ARNASA, two similarly designed randomised double-blind placebo-controlled trials in participants with COPD, frequent exacerbations, and current or former smoking, irrespective of blood eosinophil count or chronic bronchitis. A total of 2,682 participants were randomised 1:1:1 to astegolimab 476 mg every two weeks, every four weeks, or placebo for 52 weeks on top of optimised maintenance therapy.
Moderate or severe exacerbations fell by 15% with two-weekly dosing (adjusted rate ratio 0.85, 95% CI 0.76 to 0.96, p=0.0077) and 12% with four-weekly dosing (rate ratio 0.88, 95% CI 0.78 to 0.99, p=0.0265). Severe exacerbations fell by 32% with two-weekly dosing (rate ratio 0.68, 95% CI 0.52 to 0.87, p=0.0028), described as nominally significant. Tolerability was good.
The severe exacerbation figure is the one that would matter to a patient — those are the admissions. But it sits below the primary endpoint in a hierarchical testing plan and is reported as nominal, so it should be read as encouraging rather than established.
What is genuinely new is the absence of a biomarker gate. If a COPD biologic works without requiring an eosinophil count above a threshold, the eligible population is far larger, which raises an affordability question rather than settling it. At biologic prices, a 15% relative reduction in exacerbations in an unselected population is a difficult health economic case anywhere, and an impossible one in most Indian practice.
- Astegolimab reduced moderate or severe exacerbations by 15% with two-weekly dosing in an eosinophil-unselected COPD population
- The 32% reduction in severe exacerbations is nominally significant and hierarchically gated — encouraging, not established
- Optimise inhaled triple therapy, adherence and inhaler technique before considering any biologic
- Expect cost, not eligibility, to be the limiting factor if this reaches the market
- Two-weekly dosing outperformed four-weekly on both endpoints, which is relevant to any future dosing decision
The statistics, in plain English
A rate ratio of 0.85 with an interval of 0.76 to 0.96 excludes no effect, but its upper bound sits close to 1.0, so the plausible benefit ranges from 4% to 24% — the point estimate of 15% is the middle of a fairly wide range. The severe exacerbation result carries a specific caveat: the trials used a hierarchical testing plan in which secondary endpoints are only formally tested if the primary succeeds, and the authors describe this result as nominally significant, meaning it was not part of the confirmatory sequence. Nominal significance in a pooled secondary endpoint is a reason to design the next trial, not to quote the number as proven.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free